Summary of findings 2. Pulpectomy compared with pulpectomy using alternative medicament for extensive decay in primary teeth.

Pulpectomy compared with pulpectomy using alternative medicament for extensive decay in primary teeth
Population: children with extensive decay in primary teeth Settings: primary care Intervention: pulpectomy with 1 type of medicament Comparison: pulpectomy using alternative medicament
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	Number of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk
	Control	Experimental
Endoflas versus ZOE
Clinical failure (6 months)	128 per 1000	33.3 per 1000 (6.4 per 1000 to 192 per 1000)	RR 0.26 (0.05 to 1.50)	80 (2 studies)	⊕⊕⊕⊝ moderate1	One trial assessed failure at 12 months: RR 1.00, 95% 0.07 to 14.55
Radiological failure (6 months)	128 per 1000	33.3 per 1000 (6.4 per 1000 to 192 per 1000)	RR 0.26 (0.05 to 1.50)	80 (2 studies)	⊕⊕⊕⊝ moderate1
Metapex versus ZOE
Clinical failure (12 months)	97 per 1000	68.9 per 1000 (14.6 per 1000 to 323 per 1000)	RR 0.71 (0.15 to 3.33)	62 (2 studies)	⊕⊕⊕⊝ moderate1	Results similar at 6 months
Radiological failure (12 months)	129 per 1000	129 per 1000 (40 per 1000 to 421.8 per 1000)	RR 1.00 (0.31 to 3.27)	62 (2 studies)	⊕⊕⊕⊝ moderate1	Results similar at 6 months
Other comparisons assessed in more than one trial that had treatment failures
Clinical failure	The quality of the evidence was rated as low for 1 comparison: Vitapex versus ZOE (favouring ZOE)2
Radiological failure	The quality of the evidence was rated as low for 2 comparisons: Vitapex versus ZOE2 (favouring ZOE); calcium hydroxide versus ZOE3

^1. Downgraded 1 level due to imprecision
 ^2. Downgraded 2 levels due to very substantial inconsistency
 ^3. Downgraded 1 level due to substantial inconsistency and 1 level due to imprecision